Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flow from operating activities
Net income (loss)	$ 124,044	$ (21,319)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation expense	2,558	2,319
Depreciation	1,075	2,812
Amortization of premiums and discounts on marketable securities	(17)	21
Loss on disposal of fixed assets	44
Changes in operating assets and liabilities:
Accounts receivable	(25,000)
Related party collaboration receivable	(71)	526
Prepaid expenses and other current assets	1,411	(185)
Operating lease, right-of-use assets	469	1,080
Accounts payable	1,132	626
Accrued expenses	(122)	(3,494)
Operating lease liabilities	(683)	(1,307)
Deferred revenue	18,725	53,347
Net cash provided by operating activities	123,565	34,426
Cash flow from investing activities
Purchases of property and equipment	(509)	(38)
Purchases of marketable securities		(19,960)
Proceeds from sales and maturities of marketable securities	15,000
Net cash provided by (used in) investing activities	14,491	(19,998)
Cash flow from financing activities
Proceeds from the exercise of stock options	185	12
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	31,121
Net cash provided by financing activities	31,306	12
Net increase in cash, cash equivalents, and restricted cash	169,362	14,440
Cash, cash equivalents, and restricted cash, beginning of period	100,474	119,212
Cash, cash equivalents, and restricted cash, end of period	269,836	133,652
Supplemental disclosure of cash and non-cash activities
Capital expenditures incurred but not yet paid	$ 109	$ 228